靶向阿尔茨海默病的扭曲Aβ通路：炒作和障碍。

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-09-27 DOI:10.1007/s10787-025-01983-9

Hayder M Al-Kuraishy, Ghassan M Sulaiman, Ali I Al-Gareeb, Hamdoon A Mohammed, Ali K Albuhadily, Mosleh M Abomughaid

{"title":"靶向阿尔茨海默病的扭曲Aβ通路：炒作和障碍。","authors":"Hayder M Al-Kuraishy, Ghassan M Sulaiman, Ali I Al-Gareeb, Hamdoon A Mohammed, Ali K Albuhadily, Mosleh M Abomughaid","doi":"10.1007/s10787-025-01983-9","DOIUrl":null,"url":null,"abstract":"Alzheimer's disease (AD) is the most common neurodegenerative brain disease due to the progressive accumulation of amyloid protein (Aβ) and neurofibrillary tangles (NFTs). These neuropathological changes trigger excitotoxicity, inflammation, oxidative stress, and neuronal apoptosis. Therefore, targeting Aβ may be operative in the management of AD. However, suppression of normal Aβ, which regulates brain cognitive function, may induce cognitive impairment in healthy individuals. Therefore, this review aims to discuss the potential physiological role of normally present Aβ and neurotoxic Aβ in healthy brains and AD patients, respectively. In addition, in this review, we discussed and explained how targeting neurotoxic Aβ could be effective in the management of AD.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting the awry Aβ pathway in Alzheimer's disease: hype and hurdles.\",\"authors\":\"Hayder M Al-Kuraishy, Ghassan M Sulaiman, Ali I Al-Gareeb, Hamdoon A Mohammed, Ali K Albuhadily, Mosleh M Abomughaid\",\"doi\":\"10.1007/s10787-025-01983-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alzheimer's disease (AD) is the most common neurodegenerative brain disease due to the progressive accumulation of amyloid protein (Aβ) and neurofibrillary tangles (NFTs). These neuropathological changes trigger excitotoxicity, inflammation, oxidative stress, and neuronal apoptosis. Therefore, targeting Aβ may be operative in the management of AD. However, suppression of normal Aβ, which regulates brain cognitive function, may induce cognitive impairment in healthy individuals. Therefore, this review aims to discuss the potential physiological role of normally present Aβ and neurotoxic Aβ in healthy brains and AD patients, respectively. In addition, in this review, we discussed and explained how targeting neurotoxic Aβ could be effective in the management of AD.\",\"PeriodicalId\":13551,\"journal\":{\"name\":\"Inflammopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10787-025-01983-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01983-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

阿尔茨海默病（AD）是由于淀粉样蛋白（Aβ）和神经原纤维缠结（nft）的进行性积累而引起的最常见的神经退行性脑疾病。这些神经病理变化引发兴奋毒性、炎症、氧化应激和神经元凋亡。因此，靶向Aβ可能在AD的治疗中有效。然而，抑制正常的调节大脑认知功能的Aβ可能会导致健康个体的认知障碍。因此，本文旨在探讨正常存在的Aβ和神经毒性Aβ在健康大脑和AD患者中的潜在生理作用。此外，在这篇综述中，我们讨论并解释了靶向神经毒性Aβ如何有效地治疗AD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeting the awry Aβ pathway in Alzheimer's disease: hype and hurdles.

Alzheimer's disease (AD) is the most common neurodegenerative brain disease due to the progressive accumulation of amyloid protein (Aβ) and neurofibrillary tangles (NFTs). These neuropathological changes trigger excitotoxicity, inflammation, oxidative stress, and neuronal apoptosis. Therefore, targeting Aβ may be operative in the management of AD. However, suppression of normal Aβ, which regulates brain cognitive function, may induce cognitive impairment in healthy individuals. Therefore, this review aims to discuss the potential physiological role of normally present Aβ and neurotoxic Aβ in healthy brains and AD patients, respectively. In addition, in this review, we discussed and explained how targeting neurotoxic Aβ could be effective in the management of AD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]